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Abstract
End-stage renal disease patients treated with hemodialysis are characterized by a special
diet, increased oxidative stress, cardiovascular morbidity and mortality, as well as many
other complications such as inflammation-malnutrition syndrome, muscle cramps, and
anemia. Worldwide efforts are focused on reducing hemodialysis complications to
increase survival in these patients. In vitro and in vivo studies proved that vitamin E has
many beneficial effects such as: decreases reactive oxygen species synthesis, improves
antioxidant defense system, inhibits lipids peroxidation and reduces atherosclerosis, and
ameliorates anemia treatment. Mechanisms of action are complex and not fully under-
stood. However, there are particularities in regards of vitamin E intake, metabolism, and
clearance in patients treated with hemodialysis. Supplementation of vitamin E in these
patients has been intensively studied, and it is still under debate. Oral administration and
vitamin E-coated membranes for dialysis have been tried. Clinical practice guidelines
tried to underline when and how much vitamin E to be given to be safe and cost-
beneficial. The current chapter aims to synthesize all these issues.
Keywords: hemodialysis, vitamin E deficiencies, oxidative stress, anemia, cardiovascular
diseases, vitamin E supplementation
1. Introduction
Hemodialysis (HD) patients are a special population with many particularities in regard of
nutrition, metabolism, inflammation and oxidative stress, morbidity, and mortality. Contacts
with extracorporeal dialysis membranes generate inflammation and oxidative stress and the
entire cascade of complications. Intake, metabolism, and clearance of many nutrients are
limited or disturbed, and vitamin E is one of them. On the other hand, beneficial effects of
vitamin E come to recommend its supplementation in order to limit oxidative stress and other
complications in hemodialysis patients.
© 2018 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms of the Creative
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2. Particularities of HD patients
• dietary restrictions
• increased oxidative stress (as displayed in Figure 1)
• increased inflammation markers and malnutrition inflammation syndrome
• muscle cramps during dialysis
• disturbances in lipid profile
• increased cardiovascular risk
3. Status of vitamin E in HD patients
The level of vitamin E in HD patients is influenced by dietary intake, particularities in metab-
olism and clearance. The plasma level of vitamin E is usually normal, even though there are
studies that found predialysis low levels of alpha-tocopherol. However, the number of patients
included was small and similar results have not been identified in other larger studies. Gastro-
intestinal disturbances in uremic patients might lead to poor absorption and this could be an
explanation for low plasma levels of vitamin E identified in some HD patients, while increased
consumption is another one [1–4].
Profile of vitamin E status in these patients is as follows:
• limited intake
• not cleared by dialysis
Figure 1. Oxidative stress in hemodialysis patients.
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• metabolism disturbances
• normal/reduced plasma levels
• reduced level in cellular membranes
3.1. Intake
Usually, HD patients have sufficient daily dietary intake of vitamin E, but sources of vitamin E
are limited and mainly represented by vegetable oils. Many other sources are restricted in
Food Portion size Vitamin E
(milligrams of
alpha-tocopherol)
A/ARP/NA in
hemodialysis
patients
Additional observations
Fats and oils
Vegetable oil, wheat germ 5 mL (1 tsp) 7 NA High content of phosphorus
Vegetable oil (sunflower,
safflower)
5 mL (1 tsp) 2 A —
Vegetables and fruits
Spinach, cooked ½ cup 3–4 ARP High content of potassium
Tomato sauce 125 ml (½ cup) 2 NA High content of potassium
Pumpkin, canned 1 cup 3 NA High content of potassium
Collard greens 1 cup 2 ARP High content of potassium
Avocado ½ fruit 4 NA High content of potassium
Mango 1 whole 1.9 NA High content of potassium
Asparagus, cooked 1 cup 2.2 NA High content of potassium
Red peppers, raw 1/2 2 ARP High content of potassium
Grains products
Cereal, wheat germ 30 g (1/4 cup) ARP High content of phosphorus
Meat and alternatives
Tuna, canned with oil 75 g 2 ARP High contents of phosphorus
Sardines, canned with oil 75 g 2 ARP High contents of phosphorus
Herring, cooked 75 g 1.5 ARP High contents of phosphorus
Egg, cooked 2 large 2.5 ARP High contents of phosphorus
and lipids
Nuts and seeds
Sunflower seeds ¼ cup 8–10 NA High contents of phosphorus
Almonds ¼ cup 9 NA High contents of phosphorus
Peanuts ¼ cup 3 NA High contents of phosphorus
Peanut butter 2tbsp 3 NA High contents of phosphorus
Hazelnuts ¼ cup 5 NA High contents of phosphorus
Table 1. Sources of vitamin E for hemodialysis patients.
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these patients because of its increased phosphorus and/or potassium content. Table 1 displays
vitamin E containing foods which are allowed (A), allowed with restricted portions size (ARP),
or not allowed (NA) in patients undergoing chronic hemodialysis [4–6].
3.2. Metabolism and clearance
Vitamin E is a lipophilic vitamin. Hemodialysis membranes remove only hydrophilic sub-
stances, so that alpha-tocopherol cannot be cleared by hemodialysis. It should be unlikely that
vitamin E levels should be low in these patients as long as the intake is adequate, but abnor-
malities in absorption and metabolism of alpha-tocopherol have been reported.
Tocopherol is metabolized to carboxyethyl-hydroxychromans (CEHC), which are water-
soluble compounds excreted by the kidneys. These metabolites accumulate in uremic patients,
but as they are water soluble, they might be removed by dialysis membranes also. This could
be an explanation for the results of a study from USA that found that even though CEHC
levels increased after 30 days of alpha-tocopherol supplementation, they did not increase any
more with further treatment [4, 7].
A reduction of vitamin E in cellular membranes has been noted in HD patients, suggesting that
a decreased uptake of alpha-tocopherol by different tissues is happening, but the mechanism is
not known. Some studies showed a disproportion between plasma tocopherol and lipids, as
well as a low level of gamma-tocopherol and CEHC accumulation in patients undergoing
chronic hemodialysis.
4. Effects of vitamin E in hemodialysis patients
• antioxidant agent
• antiatherosclerotic
• hypolipidemic
• ameliorates recurrent muscle cramps
• reduces erythropoietin doses
A schematic representation of mechanisms leading to these effects of vitamin E in hemodialy-
sis patients is displayed in Figure 2.
4.1. Antioxidant agent
Increased reactive oxygen species (ROS) production was observed in hemodialysis patients, in
response to inflammation and extracorporeal membranes. Markers of lipid peroxidation are
increased in these patients, while catalase and superoxide dismutase activity are decreased.
5-lipoxygenase branch of the arachidonate cascade is only responsible for membrane peroxi-
dation, oxidative stress, and apoptosis of leucocytes in hemodialysis patients.
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Vitamin E might directly inhibit 5-lipoxygenase in peripheral blood monocytes and partially
control the lipid peroxidation and oxidative stress [8, 9].
Early studies showed that vitamin E acts as a scavenger for ROS in hemodialysis patients.
Other researchers found that gamma-tocopherol is a detoxifier of peroxynitrile radicals. More
recent in vitro studies found that vitamin E-coated dialysis membranes reduce intracellular
ROS in monocytes and maintain normal activity of Cu/Zn superoxide dismutase [4, 10–12].
Asymmetric dimethylarginine (ADMA) is an endogenous inhibitor of endothelial nitric oxide
(NO) synthase and it is increased in hemodialysis patients. Vitamin E acts as an inhibitor of
ADMA and increases the activity of NO synthase [13, 14].
Pertosa et al. demonstrated that vitamin E-coated dialysis membranes reduce activation of Jun
N-terminal kinase [15].
4.2. Antiatherosclerotic effect
Vitamin E acts at the cellular level interfering with reactions implied in the progression of
atherosclerosis such as:
• reduces smooth muscle cell proliferation;
• inhibits platelet aggregation and monocyte adhesion induced by superoxide anions;
• reduces lipids peroxidation in monocytes;
• decreases oxidized low-density lipoproteins uptake;
• reduces activation of Jun-N terminal kinase;
Figure 2. Effects of vitamin E on hemodialysis patients.
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• decreases ADMA and increases NO synthase activity and NO synthesis; and
• reduces cytokine production.
All these listed above have been found in small in in vitro or in vivo studies [8–17].
There are two large controlled trials on patients with renal failure, SPACE and HOPE studies,
that found either a significant reduction in cardiovascular risk and myocardial infarction in
end-stage renal disease patients treated with oral alpha-tocopherol as compared to placebo, or
similar effect of vitamin E treatment and ramipril on cardiovascular outcome in patients with
mild and moderate renal failure [18, 19].
4.3. Hypolipidemic effect
It was demonstrated that vitamin E reduces lipid peroxidation and it decreases electronegatively
charged LDL-subfraction, but if it also reduces the triglycerides or total cholesterol, it is uncer-
tain. Some studies found that short-term high doses of vitamin E had no benefits in a majority of
renal patients in regards to their circulating levels of high-density lipoprotein cholesterol [16, 17].
4.4. Ameliorates muscle cramps
Vitamin E-deficient muscle in animals has been shown to provide increased susceptibility to
peroxidative damage.
Radical-mediated oxidative damage of skeletal muscle membranes has been implicated in the
fatigue process. Moreover, in hemodialysis patients, ROS-mediated damages occur during
hemodialysis-induced muscle hypoperfusion and ischemia, as well as because of activation of
macrophages and leukocytes passing dialysis membranes. Vitamin E is a major chain-breaking
antioxidant that has been shown to reduce contraction-mediated oxidative damage. Vitamin E
deficiency would adversely affect muscle contractile function, resulting in a more rapid devel-
opment of muscular fatigue during exercise [4, 20].
4.5. Erythropoietin doses reduction
Anemia is an important cause of morbidity and mortality in chronic hemodialysis patients.
Treatment with erythropoiesis-stimulating agents is influenced by many factors that can induce
erythropoietin resistance, such as:
• bleeding
• iron deficiency
• folate and vitamin B12 deficiency
• inflammation
• oxidative stress
An imbalance between oxidant and antioxidant system in hemodialysis patients is well
known. Any studies found low levels of superoxide dismutase and decreased activity of
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erythrocyte superoxide dismutase in erythrocyte membranes, leading to increased reactive
oxygen species production, increased anemia, and resistance to erythropoietin treatment.
Some authors found that vitamin E supplementation was followed by increased activity of
erythrocyte superoxide dismutase, improving anemia and erythropoietin responsiveness in
these patients [4, 10, 21].
5. Vitamin E supplementation in hemodialysis patients
5.1. Oral supplementation
The European Best Practice Guidelines on Renal Nutrition recommend a daily supplement of
400–800 IU for the secondary prevention of cardiovascular events and recurrent muscle cramps
[4, 20, 22].
5.2. Vitamin E-coated membranes
Vitamin E-coated membranes were used in hemodialysis to increase membrane biocompati-
bility and to reduce reactive oxygen species production [23–28].
Effects of vitamin E-coated dialysers [23–28]:
• reduce the levels of advanced glycation end products
• reduce reactive oxygen species
• prevent monocyte activation
• improve the functional capacity of white blood cells population
• reduce lipid peroxidation
• reduce intima-media thickness into carotid artery
• reduce the percentage of dysmorphic red blood cells
• reduce erythropoietin doses
Disadvantages of vitamin E-coated membranes:
• expansive
• not widely available
6. Side effects of vitamin E supplementation
Usually, no side effects have been seen using doses of 400–800 UI/d, even though, in prolonged
administration, some of the effects listed below could be possible [20, 22]:
• accumulation of metabolites;
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• paradoxical pro-oxidant effects due to the reduction of antioxidant defense system com-
ponents;
• bleeding, diarrhea, blurry vision, and headache are rare.
In conclusion, vitamin E proved its antioxidant effects in hemodialysis patients, decreasing
ROS synthesis and cellular damages, reducing lipid peroxidation, platelet aggregation and
limiting atherosclerosis, improving antioxidant defense and ameliorating anemia treatment in
hemodialysis patients. It is safe to use doses of vitamin E that should not exceed 1000 Ui/d in
selected hemodialysis patients, especially to reduce cardiovascular risk, improve muscle
cramps, and reduce required erythropoietin doses.
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